LUNG CANCER

Roy S. Herbst, MD, PhD, discussed the upcoming conference on July 29-31, which will follow a hybrid format with some faculty and attendees participating online and others participating in person.

In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discuss the findings from cohort 5 of the ZENITH20 study including the strategy of splitting the dose in half to reduce adverse events associated with poziotinib.

Robert Coleman, MD, FACOG, FACS, discusses key advances in precision medicine in lung cancer.

Corey J. Langer, MD, led a peer discussion around novel targets for adjuvant non–small cell lung therapy.

Luis Raez, MD, Hdiscussed the case of a 59-year-old patient with RET-mutated lung cancer.

The combination of durvalumab, tremelimumab, and chemotherapy showed statistically significant and clinically meaningful overall survival benefit compared to chemotherapy alone for the first-line treatment of patients with metastatic non-small cell lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Ticiana Leal, MD, discussed the case of a patient with non–small cell lung cancer with a group of peers.

Xiuning Le, MD, PhD, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Ravi Salgia, MD, PhD, discussed the case of a 59-year-old patient with non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

The combination of oleclumab and osimertinib was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer with an EGFR mutation after progression on an EGFR tyrosine kinase inhibitor.

During a virtual Targeted Oncology Case-Based Roundtable event, Rodolfo Bordoni, MD, discussed recent clinical trials in the extensive-stage small cell lung cancer space.

Jessica Bauman, MD, reviewed data from the LIBRETTO-001 and ARROW trials which show the efficacy and safety of selpercatinib and pralsetinib for the treatment of patients with RET fusion-positive lung cancer.

The FDA has granted a priority review to mobocertinib as a treatment for adult patients with EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.

In an interview with Targeted Oncology following the FDA approval announcement for trilaciclib, Jared Weiss, MD, an assistant professor of medicine at the University of North Carolina Chapel Hill, discusses the use of trilaciclib in clinical practice and how it can improve patient quality-of-life by reducing the rate of neutropenia.

An expert in the treatment of lung cancer gives insight for the sequencing of ALK inhibitors following disease progression, highlighting the instances of the development of brain involvement and rebiopsy.

An expert in the treatment of lung cancer gives insight for the sequencing of ALK inhibitors following disease progression, highlighting the instances of the development of brain involvement and rebiopsy.

Karen Reckamp, MD, discusses the design, practical implications, and important findings from the ALTA-1L clinical trial.

An expert in the treatment of lung cancer discusses the use of brigatinib in this patient case and in general use for ALK+ metastatic NSCLC.

Karen Reckamp, MD, reviews recent therapeutic findings and the treatment spectrum for ALK+ NSCLC, as well as her clinical experience in using some of these treatments.

Karen Reckamp, MD, provides an overview of the case of a 68-year-old woman with ALK+ NSCLC, including the initial presentation, clinical work-up, treatment, and the importance of molecular testing.

Karen Reckamp, MD, comments on the management and treatment of a 68-year-old woman with ALK+ NSCLC, as well as data demonstrated in the ALTA-1L trial, use of brigatinib, and her own clinical experiences.

For patients non–small cell lung cancer who previously progressed on chemotherapy and immune checkpoint inhibitors, ceralasertib plus durvalumab proved effective compared with patients with the same profile who received durvalumab alone, according to findings from the ongoing HUDSON study.

During a virtual Targeted Oncology Case-Based Roundtable event, Alexander Spira, MD, PhD, discusses when the use of durvalumab followed by chemoradiotherapy is appropriate for patients with unresectable stage III non–small cell lung cancer.

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.

During a virtual Targeted Oncology Case-Based Roundtable event, Kartik Konduri, MD, discussed the case of a 58-year-old patients with small cell lung cancer.